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nhibition of the putative coatomer protein I (COPI) vesicle
tethering complex, giantin–p115–GM130, may contribute
to mitotic Golgi breakdown. However, neither this, nor the
 
role of the giantin–p115–GM130 complex in the maintenance
of Golgi structure has been demonstrated in vivo. Therefore,
we generated antibodies directed against the mapped bind-
ing sites in each protein of the complex and injected these
into mammalian tissue culture cells. Surprisingly, the injected
anti-p115 and antigiantin antibodies caused proteasome-
mediated degradation of the corresponding antigens. Reduc-
I
 
tion of p115 levels below detection led to COPI-dependent
Golgi fragmentation and apparent accumulation of Golgi-
derived vesicles. In contrast, neither reduction of giantin
below detectable levels, nor inhibition of p115 binding to
GM130, had any detectable effect on Golgi structure or
Golgi reassembly after cell division or brefeldin A washout.
These observations indicate that inhibition of p115 can
induce a mitotic-like Golgi disassembly, but its essential role
in Golgi structure is independent of its Golgi-localized binding
partners giantin and GM130.
 
Introduction
 
The Golgi apparatus mediates processing and sorting of
newly synthesized proteins and lipids. As these reactions are
essential for completing protein synthesis and targeting in
the secretory pathway, mechanisms evolved to ensure accu-
rate inheritance of the Golgi apparatus during cell division.
At the onset of mitosis, the mammalian Golgi apparatus
undergoes a dramatic breakdown of its interphase structure.
Subcellular fractionation and microscopy experiments indi-
cate that it is converted from a juxtanuclear ribbon of
stacked membranes into a large number of small vesicles
dispersed mostly throughout the mitotic cytoplasm (Lucocq
et al., 1989; Misteli and Warren, 1995; Jesch and Linstedt,
1998; but see also Zaal et al., 1999). Uniform dispersal of
Golgi-derived vesicles can explain accurate Golgi partition-
ing into daughter cells, but the mechanism of Golgi vesicu-
lation is unknown.
Our current understanding concludes that kinases active
at the G2/M transition, notably cyclin-dependent kinase I
and mitogen-activated protein kinase kinase/extracellular
signal–regulated protein kinase (Achárya et al., 1998; Lowe
et al., 1998; Kano et al., 2000), carry out phosphorylation
reactions that lead, either directly or indirectly, to the inhibi-
tion of Golgi vesicle docking and fusion, which are funda-
mental processes underlying transport in the Golgi stack.
The transport of newly synthesized proteins, termed cargo,
through the Golgi stack involves their progressive encounter
with modifying enzymes enriched in either the cis-, medial-,
or trans-cisternal subcompartments. This is in part due to
both the vesicle-mediated transport of cargo between adjacent
cisternae (Rothman, 1994) and the ongoing anterograde
progression of cargo-containing cisternae through the stack
(Bonfanti et al., 1998). In the latter case, cisternal progres-
sion occurs as retrieval vesicles carry the modifying enzymes
from later subcompartments backward to earlier subcom-
partments (Glick et al., 1997; Love et al., 1998; Lanoix et
al., 1999). Thus, at M-phase, the continued formation of
vesicles containing cargo and/or enzymes without their
docking and fusion would lead to vesiculation of the organelle
(Warren et al., 1995). Because the identified mitotic Golgi
vesicles contain Golgi enzymes and other Golgi residents, it
follows that these vesicles are probably produced by the same
sorting reaction that produces retrieval vesicles during nor-
mal interphase trafficking. Alternatively, these vesicles could
be produced by a mitotic modification of the cargo–vesicle
sorting reaction allowing the incorporation of Golgi resi-
dents (Warren, 1985). In either case, evidence indicates that
the mitotic Golgi vesicle formation reaction is largely medi-
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ated by the coatomer protein I (COPI)* complex (Misteli
and Warren, 1994, 1995), which suggests that COPI vesicle
docking and fusion components may be inhibited at the G2/M
transition.
Importantly, the proteins implicated in COPI vesicle
docking undergo alterations in their phosphorylation state at
mitosis. The mitotic phosphorylation of at least one of these,
Golgi matrix protein 130 (GM130), reduces its ability to
bind its putative docking partner p115 (Nakamura et al.,
1997). Collectively, the proteins GM130, Golgi reassembly
stacking protein 65 (GRASP65), p115, and giantin are re-
ferred to as tethering proteins because they are thought to
form a long complex capable of linking COPI vesicles to the
Golgi apparatus over considerable distances (Sönnichsen et
al., 1998). Giantin is a COOH-terminally anchored Golgi
integral membrane protein (Linstedt et al., 1995) at least
partially present in COPI vesicles (Sönnichsen et al., 1998).
Giantin has a long rod-shaped cytoplasmic domain contain-
ing a p115 binding site in its predicted outermost NH
 
2
 
-ter-
minal coiled-coil segment (Lesa et al., 2000; Linstedt et al.,
2000). This site binds an acidic domain at the COOH ter-
minus of the peripheral membrane protein p115 (Linstedt et
al., 2000). This same acidic stretch in p115 also binds
GM130 (Nelson et al., 1998; Linstedt et al., 2000). Giantin
and GM130 compete to bind to p115 under certain in vitro
conditions (Linstedt et al., 2000), however under different
conditions, p115 is able to link giantin to GM130 (Dirac-
Svejstrup et al., 2000). The simultaneous binding of p115 to
Golgi cisterna–localized GM130 and COPI-localized gian-
tin could link COPI vesicles to the Golgi membrane (Sön-
nichsen et al., 1998) because GM130 is stably bound to
GRASP65, which is attached to the Golgi apparatus via a
lipid anchor (Barr et al., 1997). Indeed, in vitro association
of COPI vesicles to the Golgi membrane is blocked by anti-
giantin antibody treatment of the COPI vesicles, anti-
GM130 treatment of the Golgi membranes, or depletion of
p115 (Sönnichsen et al., 1998). Therefore, inhibition of the
p115–GM130 interaction by mitotic phosphorylation of
GM130 by cyclin-dependent kinase I could account for mi-
totic Golgi vesiculation (Lowe et al., 1998).
Nevertheless, the precise role of the Golgi-localized tether
proteins is complicated by their implication in a diverse set
of reactions. The initial characterization of p115 was based
on its essential role in an in vitro transport reaction designed
to measure cis- to medial-Golgi transfer of vesicular stomati-
tis virus glycoprotein (Waters et al., 1992). Subsequently, it
was also found to mediate fusion of transcytotic vesicles to
acceptor membranes (Barroso et al., 1995). More recently,
p115, giantin, GM130, and GRASP65 were revealed as a re-
quirement for both cisternal regrowth and cisternal stack-
ing (two subreactions during in vitro Golgi reassembly
after mitotic fragmentation) (Shorter and Warren, 1999).
GRASP65, as well as the related GRASP55, also play roles
in Golgi stacking independent of GM130 (Barr et al., 1998;
Shorter et al., 1999). p115 is also required for ER to Golgi
transport in semi-intact cells, where it is recruited to COPII-
coated vesicles by transient interaction with Rab1 followed
by stable interaction with a vesicle SNARE protein complex
containing syntaxin5, sly1, membrin, and rbet1 (Allan et al.,
2000), and mediates translocation of ER–Golgi intermedi-
ate compartment (ERGIC) from peripheral sites to the
Golgi stack (Alvarez et al., 1999). Interestingly, once trans-
port intermediates reach the Golgi region, evidence suggests
that GM130/GRASP65 functions first, perhaps in binding
vesicle-localized p115, whereas subsequent steps involve gi-
antin (Alvarez et al., 2000).
The diversity of these reactions suggests that p115 and its
binding partners mediate a number of distinct steps involv-
ing membrane–membrane recognition. As the purpose of
docking is to achieve a specific interaction between vesicle
and target, it is important to determine whether specificity
at each step is achieved by the use of distinct binding part-
ners. Furthermore, the number of distinct in vitro reactions
requiring tether proteins certainly raises the question of
whether the corresponding in vivo reactions require them as
well. For example, the belief that inhibition of p115–
GM130 interactions causes mitotic Golgi breakdown is not
supported by the finding that the microinjection of a pep-
tide that prevents binding of p115 to GM130 leads to no
apparent Golgi breakdown (Seemann et al., 2000). On the
other hand, the microinjection of anti-p115 antibodies
causes Golgi breakdown (Alvarez et al., 1999). This discrep-
ancy leads to the hypothesis that p115 has an essential role
in Golgi biogenesis independent of its interaction with
GM130. As GM130 and giantin bind the same domain in
p115, the injected GM130 NH
 
2
 
-terminal peptide would
presumably also inhibit p115–giantin complex formation.
Therefore, p115’s essential role could be independent of
both giantin and GM130, the two proteins that it is thought
to bridge during COPI vesicle docking.
We sought to test this hypothesis and further characterize
the role of p115 in the regulation of Golgi structure in rela-
tion to its binding partners giantin and GM130 in vivo. An-
tibodies were made against the corresponding binding sites
of each protein and injected into HeLa cells. Unlike giantin
and GM130, the inhibition of p115 alone in interphase cells
induced apparent COPI-dependent Golgi vesiculation. This
suggests that p115 plays a role in maintenance of Golgi
structure that may be relevant to mitotic Golgi breakdown,
but this role is independent of its interactions with giantin
and GM130.
 
Results
 
Anti-p115 antibody microinjection induces 
proteasome-dependent p115 degradation
 
To develop an inhibitory antibody against p115, polyclonal
antibodies were generated against a glutathione 
 
S
 
-transferase
(GST)–p115 fusion protein containing the p115 COOH
terminus. The acidic COOH terminus of p115 mediates its
interaction with giantin and GM130 (Nelson et al., 1998;
Linstedt et al., 2000). After affinity purification, the anti-
p115 antibodies and a corresponding population of control
 
*Abbreviations used in this paper: BFA, brefeldin A; CBM, cyclohex-
anebis(methylamine); COP, coatomer protein; ERGIC, ER–Golgi inter-
mediate compartment; GM130, Golgi matrix protein of 130 kD;
GPP130, Golgi phosphoprotein of 130 kD; GRASP, Golgi reassembly
stacking protein; GST, glutathione 
 
S
 
-transferase; NRK, normal rat kidney. 
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anti-GST antibodies were microinjected into cultured HeLa
cells. At various time points after injection, the cells were
fixed and double stained to simultaneously detect the in-
jected antibody as well as the cellular p115. As expected, un-
injected cells (Fig. 1), as well as cells injected with the con-
trol anti-GST antibodies (unpublished data), exhibited the
juxtanuclear and cytoplasmic staining pattern that is charac-
teristic of p115, a peripheral membrane protein predomi-
nately localized to Golgi membranes. In contrast, injection
of anti-p115 led to a time-dependent loss of the cellular
p115. 10 min after injection, the cytoplasmic p115 staining
became significantly more punctate, presumably due to
cross-linking induced by antibody binding (Fig. 1 A). 30
min after injection, the juxtanuclear p115 pattern also be-
came punctate and at this time point there was a marked loss
of cytoplasmic staining (Fig. 1 B). 2 h after injection most, if
not all, p115 staining was absent (Fig. 1 C), and p115 stain-
ing remained absent at 4 h (Fig. 1 D) and 6 h after injection
(unpublished data). These observations suggest that the in-
jected anti-p115 antibody cross-links cellular p115 and
somehow induces its degradation.
This effect appeared specific to p115 as the abundance of
other proteins in anti-p115–injected cells, including two of
its known binding partners, was not detectably altered (see
below). In addition, three observations argue against the
possibility that binding of the injected polyclonal antibody
blocked access of the monoclonal antibody used for detec-
tion of cellular p115. First, the monoclonal antibody binds
to a region of p115 outside of the COOH-terminal portion
used to generate the polyclonal antibody. Second, staining
for the injected polyclonal antibody produced a juxtanuclear
pattern at early time points, that became punctate at 30 min
and disappeared at later time points (unpublished data).
Thus, the apparent loss of p115 was also detected with the
injected polyclonal antibody. Third, we obtained no evi-
dence that the polyclonal antibody could block staining of
cellular p115 by the monoclonal antibody in experiments
where digitonin-permeabilized cells held on ice were first in-
cubated with the polyclonal and then the monoclonal anti-
body. After fixation and detection with fluorescent second-
ary antibodies both the polyclonal and monoclonal antibody
patterns colocalized on the Golgi membrane.
To test whether the loss of cellular p115 after anti-p115 mi-
croinjection was due to targeted degradation, we performed
similar microinjection experiments in the presence and absence
of a proteasome inhibitor. As expected, control cells examined
3 h after injection exhibited no detectable p115 staining (Fig. 1
E). In contrast, cells treated with the proteasome inhibitor
MG132 during the 3 h after injection incubation exhibited
readily detectable juxtanuclear p115 staining (Fig. 1 F). The
staining pattern was markedly punctate suggesting that the in-
jected antibodies had cross-linked p115 causing it to cluster on
the Golgi membrane. In the absence of proteasome activity this
failed to cause its degradation. These observations suggest that
the binding of the injected antibody somehow targets p115 to
the proteasome perhaps by inducing its recognition by a ubiq-
uitin ligase. In any case, this provides an opportunity to study
various cell functions in the apparent absence of p115.
Figure 1. Injection of anti-p115 antibodies induces 
proteasome-dependent degradation of p115. HeLa 
cells were microinjected with affinity-purified poly-
clonal anti-p115 antibodies and stained for p115 
using an anti-p115 mAb at 10 min (A), 30 min (B), 2 h 
(C), and 4 h (D) after injection. Injected cells were 
outlined as described in Materials and methods. 
Injected, but not uninjected, cells showed a loss of 
p115 staining over time. Also shown are cells that 
were incubated for 3 h after injection in the absence 
(E) or presence (F) of 50  M MG132. Both incubations 
contained 0.005% DMSO, the solvent for the MG132 
stock solution. Presence of MG132, a proteasome 
inhibitor, prevented anti-p115–induced loss of p115 
staining. Bar, 10  m. 
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Absence of p115 induces apparent COPI-dependent 
Golgi vesiculation
 
To test the effect of p115 loss on Golgi structure, we stained
the Golgi apparatus in cells that had been incubated for vari-
ous times after microinjection of anti-p115. The staining was
performed using a monoclonal antibody that recognizes Golgi
phosphoprotein 130 (GPP130), an integral membrane com-
ponent of the cis-Golgi apparatus (Linstedt et al., 1997). The
Golgi pattern remained normal 10 min after injection (Fig. 2
A), but 30 min after injection, the Golgi apparatus was notice-
ably fragmented (Fig. 2 B). 2 h after injection, the Golgi appa-
ratus was present as dispersed fragments and there was a no-
ticeable increase in diffuse staining (Fig. 2 C). 4 h after
injection, the Golgi apparatus was almost entirely present as
diffuse cytoplasmic staining with a few larger structures, or
remnants, still visible (Fig. 2 D). A similar pattern of Golgi
breakdown was observed when giantin or GM130 was used to
mark the Golgi apparatus, and also when cells were allowed to
pass through mitosis after injection, as described below (un-
published data). Injection of control anti-GST antibodies had
no detectable effect on the Golgi apparatus at similar time
points (unpublished data). Thus, loss of p115 led to a dra-
matic breakdown of at least the early Golgi structure.
Because Golgi breakdown in cells lacking detectable p115
resulted in diffuse Golgi staining, it was possible the anti-
p115 microinjection induced Golgi vesiculation. However,
it was also possible that the diffuse staining reflected redis-
tribution of the Golgi apparatus into the ER membrane
network, similar to that induced by brefeldin A (BFA)
treatment. To distinguish between these possibilities, we
performed a digitonin permeabilization of the injected cells.
Because digitonin selectively permeabilizes the plasma mem-
brane (Eilenberg et al., 1989), this treatment allows the re-
lease of small vesicles but not the large anchored ER net-
work. The diffuse Golgi staining evident in cells 3 h after
 
injection of anti-p115 (Fig. 3 A) was essentially lost if the
cells were digitonin permeabilized before fixation (Fig. 3 B).
Note that the Golgi apparatus present in adjacent, unin-
jected cells was unaffected by the permeabilization. In a
quantitative analysis of these experiments, it was found that
upon permeabilization the dispersed cytoplasmic fluores-
cence of the Golgi marker GPP130 in anti-p115–injected
cells was reduced to the background level of cytoplasmic
fluorescence in uninjected cells (Fig. 3 C). Two findings in-
dicate that the ER was not released in these experiments.
First, p63, an integral ER protein, was not released from un-
injected or injected cells by digitonin treatment (Fig. 3 C).
Second, after BFA treatment, ER-localized GPP130 was not
released by digitonin treatment (Fig. 3 C). Thus, the Golgi
breakdown pattern induced by the absence of detectable
p115 did not reflect redistribution to the ER, but rather the
accumulation of releasable structures likely to be small vesi-
cles. This is consistent with the hypothesis that p115 medi-
ates docking of Golgi-derived vesicles.
Because the mechanism most likely to mediate Golgi vesicu-
lation is COPI vesicle formation, we next tested whether Golgi
breakdown induced by anti-p115 antibody injection is inhib-
ited by the presence of a COPI inhibitor. For these experiments
we used the drug 1,3-cyclohexanebis(methylamine) (CBM),
which causes displacement of COPI from the Golgi apparatus
(Hu et al., 1999). The advantage of CBM is that, unlike other
conditions that prevent COPI membrane association, CBM
treatment does not cause Golgi redistribution into the ER.
Nevertheless, CBM-treated cells remain competent to carry out
a number of transport steps including bi-directional ER–Golgi
transport (Hu et al., 1999). In our experiments, CBM treat-
ment led to displacement of the COPI subunit, 
 
 
 
-COP, from
the Golgi apparatus, but did not cause Golgi collapse or prevent
the BFA-induced redistribution of the Golgi system to the ER
(unpublished data). As expected, control cells examined 3 h af-
Figure 2. Absence of detectable p115 
induces Golgi breakdown. HeLa cells 
were microinjected with anti-p115 and 
stained for the Golgi apparatus using 
anti-GPP130 mAb at 10 min (A), 30 min 
(B), 2 h (C), and 4 h (D) after injection. 
Injected cells are outlined. Note the 
prominent diffuse cytoplasmic Golgi 
staining at the last time point. Images are 
representative of three experiments with 
at least 25 cells examined in each 
experiment. Uninjected cells showed a 
normal Golgi apparatus at all time 
points. Bar, 10  m. 
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ter injection exhibited a significant Golgi breakdown and accu-
mulation of the vesicle staining pattern (Fig. 4 A). In contrast,
cells treated with CBM during the 3 h after injection retained
an intact juxtanuclear Golgi apparatus that was morphologically
similar to adjacent CBM-treated, but uninjected, cells (Fig. 4
B). The CBM block of Golgi vesiculation was most likely due
to its effect on COPI rather than an indirect blockage of the an-
tibody-induced p115 degradation, because the CBM-treated,
microinjected cells exhibited the expected loss of p115 (unpub-
lished data). Thus, the absence of p115 appears to induce
COPI-mediated Golgi vesiculation.
We also considered the possibility that p115 absence actually
causes Golgi apparatus disassembly by recycling Golgi proteins
through the ER, which leads to their accumulation in a post-ER
compartment such as COPII vesicles or the ERGIC. Costain-
ing of anti-p115–injected cells for the Golgi marker, giantin
(Fig. 5 A), and the ERGIC marker, ERGIC-53 (Fig. 5 B), re-
vealed that the disassembled Golgi apparatus was almost en-
tirely distinct from the ERGIC and that the ERGIC main-
tained its normal punctate pattern. Because ERGIC-53 rapidly
cycles between the ER and ERGIC, mostly bypassing the Golgi
apparatus (Hauri et al., 2000, and references therein), and is re-
distributed to the ER under conditions of ER export blockade
(Shima et al., 1998; Lee and Linstedt, 1999), the normal ER-
GIC pattern implies that ER export and ERGIC formation/
maintenance continue in the absence of p115. If ER to ERGIC
transport persists in the absence of p115, then the lack of abun-
dant Golgi staining in the ERGIC argues against a disassembly
pathway involving the ER. To directly demonstrate ER to ER-
GIC transport, we microinjected BFA-treated cells with anti-
p115 antibodies and then performed a BFA washout. In this
case, giantin (Fig. 5 C) moved from its redistributed position in
the ER into structures that costained with ERGIC-53 (Fig.
5 D). Similar results were obtained for the Golgi marker
GPP130. These observations indicate that anti-p115–induced
Golgi breakdown is primarily direct.
 
Antigiantin antibody microinjection induces giantin 
degradation but not Golgi breakdown
 
Our finding that loss of p115 led to Golgi breakdown con-
firms a previous report that p115 is required for mainte-
nance of interphase Golgi structure (Alvarez et al., 1999).
Figure 3. Apparent release of Golgi 
vesicles upon digitonin permeabilization. 
HeLa cells were injected with anti-p115 
antibodies and were either fixed after 4 h 
(A) or were permeabilized with 0.04 mg/
ml digitonin before fixation (B). Cells were 
single stained using anti-GPP130 to 
exclude any possibility of bleedthrough. 
Interphase cells that exhibited fragmented 
Golgi staining were only present in micro-
injected areas of the coverslips. Represen-
tative examples of these are marked with 
asterisks. (C) The level of cytoplasmic 
GPP130 fluorescence excluding the Golgi 
region was quantified as described in 
Materials and methods before (open bars) 
and after (filled bars) digitonin permeabili-
zation for anti-p115–injected (INJ, n   65), uninjected (UNINJ, n   23), and BFA-treated 
cells (BFA, n   34). The analysis was also performed for the ER marker p63 (INJ, n   28; 
UNINJ, n   30). Fluorescence of the dispersed Golgi complex, but not the ER, was reduced 
to background levels after digitonin permeabilization. Bar, 10  m.
Figure 4. Anti-p115–induced Golgi breakdown is blocked by the 
COPI inhibitor CBM. Cells were injected with anti-p115 antibodies, 
incubated for 3 h in the absence (A) or presence (B) of 2 mM CBM, 
and stained for the Golgi marker GPP130. Injected cells are out-
lined. Although CBM itself slightly perturbed Golgi morphology in 
uninjected cells, its presence blocked Golgi breakdown in injected 
cells. Bar, 10  m. 
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Further, because the breakdown involved an apparent direct
vesiculation, it suggests that p115 plays a role in the docking
of Golgi-derived vesicles. Therefore, we next tested whether
the role of p115 in Golgi structure maintenance requires
binding to either of the putative tether components, giantin
or GM130. Polyclonal antibodies were generated against a
peptide containing the mapped p115 binding site in the
NH
 
2
 
 terminus of giantin. Upon microinjection into HeLa
cells, the antigiantin antibodies induced degradation of gian-
tin with a time course that was similar to the anti-p115–
induced degradation of p115. Thus, early time points exhib-
ited clustered giantin staining (unpublished data), and 2 h
after injection giantin staining was undetectable (Fig. 6 A).
The degradation was specific to giantin as other marker pro-
teins did not exhibit any reductions in staining (see below),
and giantin degradation did not occur upon injection of
control anti-GST antibodies (unpublished data). The anti-
giantin-induced giantin degradation, but not the antibody-
induced giantin clustering, was blocked in microinjected
cells incubated in the presence of the proteasome inhibitor
MG132 (Fig. 6 B). This result indicated that, similar to the
anti-p115–induced p115 degradation, the giantin degrada-
tion was proteasome mediated. Further, the absence of de-
tectable giantin persisted for at least 48 h after injection with
no apparent loss in cell viability, which allowed us to per-
form relatively long experiments with cells lacking giantin.
Surprisingly, the Golgi apparatus appeared morphologi-
cally and functionally normal in the microinjected cells lack-
ing detectable giantin. Even 16 h after microinjection, a sit-
uation where the cells remained without detectable giantin
staining for at least 14 h, there was no apparent defect in the
GPP130 (Fig. 6 C), p115 (Fig. 6 D), or KDEL receptor
(unpublished data) staining patterns based on comparison to
adjacent, uninjected cells. This strongly suggests that giantin
is not required for processes essential for maintenance of
Golgi structure, and in the absence of giantin, the Golgi
complex still mediates KDEL receptor recycling. Further-
more, p115 mediates a process essential for Golgi structure
(see above and Alvarez et al., 1999), which implies that, in
this case, p115 acts independently of giantin.
In light of these observations, we tested whether cells lack-
ing detectable giantin retained the capability to undergo
Golgi reassembly after either BFA-induced Golgi redistribu-
tion to the ER or mitosis-induced Golgi vesiculation. In-
deed, the entire cycle of BFA-induced Golgi–ER fusion and
Golgi re-emergence upon BFA washout was indistinguish-
able in microinjected and adjacent, uninjected cells, even
though the experiments were carried out under conditions
that reduced giantin levels below detection (unpublished
data). Furthermore, cells lacking detectable giantin were able
to divide (Fig. 6 E) and exhibited normal Golgi patterns
(Fig. 6 F). For these experiments, isolated single cells on
each coverslip were injected, incubated for 20 h, and ana-
lyzed. At the end of the incubation, each injected cell had
doubled indicating passage through mitosis after injection.
Normal Golgi reassembly was also evident in microinjected
cells that were costained for microtubules (Fig. 6 G) and the
Golgi complex (Fig. 6 H), and postmitotic pairs were identi-
fied by the short microtubule bundle at the site of cytokine-
sis. Therefore, cells lacking detectable giantin were viable,
exhibited a normal Golgi staining pattern, and underwent
cycles of Golgi disassembly/reassembly.
 
Microinjection of anti-GM130 antibodies that prevent 
GM130–p115 complex formation
 
Polyclonal antibodies were also generated against the NH
 
2
 
-
terminal domain of GM130, which contains its p115
binding site. Microinjection of these antibodies with sub-
sequent incubations up to 16 h had no apparent effect on
the staining patterns for giantin (Fig. 7 A), p115 (Fig. 7 B),
GPP130 (unpublished data), and KDEL receptor (unpub-
lished data). Not only was the interphase Golgi structure
normal in anti-GM130–injected cells, but BFA-induced
Golgi–ER fusion and Golgi reemergence upon BFA wash-
out was indistinguishable in microinjected and adjacent,
uninjected cells (unpublished data). Also, when isolated
single cells on each coverslip were injected and incubated
for 20 h, the cells divided normally and the daughter cells
reassembled a normal Golgi apparatus as indicated by
staining for GPP130 (Fig. 7 C).
In contrast to the unexpected antibody-induced antigen
degradation described above for anti-p115 and antigiantin,
microinjection of anti-GM130 had no apparent effect on
GM130 abundance. This was evident from the Golgi stain-
ing pattern exhibited by the injected antibody from early
time points through at least 16 h after injection; that is, the
injected antibody remained bound to GM130 on the Golgi
Figure 5. Evidence for direct Golgi disassembly in cells lacking 
p115. Cells were injected with anti-p115 antibodies, incubated for 
6 h, and then costained directly for giantin with FITC-coupled anti-
giantin pAb (A) and indirectly for ERGIC-53 with a mAb (B). Cells 
were also treated with BFA to collapse the Golgi into the ER, 
injected with anti-p115, washed to remove the BFA, incubated in 
the absence of BFA for 4 h, and then costained directly for giantin 
(C) and indirectly for ERGIC-53 (D). All cells shown were injected. 
Note the lack of Golgi staining in the ERGIC after breakdown and 
its presence after BFA washout. Bar, 10  m. 
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apparatus throughout the experiment with no apparent dim-
inution. Furthermore, no reduction in staining or alteration
in Golgi pattern was observed in microinjected cells co-
stained for cellular GM130 with a monoclonal anti-GM130
antibody (unpublished data). Therefore, we performed
binding experiments to confirm that the anti-GM130 anti-
bodies actually inhibited p115–GM130 interaction.
In the first experiment, an immobilized GST–GM130 fu-
sion protein containing its p115 binding site (Linstedt et al.,
2000) was incubated with p115-containing cell extracts in
the presence of anti-GM130 or control antibodies. Despite
the relatively high concentration of GM130 present in the
assay, the anti-GM130 antibody showed a concentration-
dependent inhibition of p115 binding, whereas control anti-
GST antibodies did not (Fig. 8 A). Thus, the anti-GM130
antibody had inhibitory activity against p115–GM130 com-
plex formation, yet its microinjection did not displace p115
from the Golgi complex (Fig. 7 B). This observation is actu-
ally consistent with previous reports indicating that versions
of p115 lacking the GM130 binding domain are still Golgi
apparatus targeted (Nelson et al., 1998); that is, p115 ap-
pears to have at least one other Golgi-localized receptor. The
receptor in question is not giantin because the giantin bind-
ing site in p115 maps to the same position as the GM130
binding site (Linstedt et al., 2000). Furthermore, co-injec-
tion of both antigiantin and anti-GM130 also did not dis-
place p115 or cause any detectable Golgi abnormality (un-
published data). Therefore, to confirm that anti-GM130
antibodies disrupt p115–GM130 interaction without block-
ing p115 membrane binding, we performed a second bind-
ing experiment.
In this experiment, membrane fractions containing bound
p115 were incubated with anti-GM130 antibodies and then
subjected to either a co-immunoprecipitation assay to test
for p115–GM130 complexes or to a centrifugation assay to
test for p115 membrane association. The co-immunoprecip-
Figure 6. Golgi maintenance and reassembly in 
the absence of detectable giantin. Cells injected 
with rabbit antigiantin antibodies were incubated 
for 2 h in the absence (A) or 3 h in the presence (B) 
of 50  M MG132 before staining with mouse anti-
giantin antibodies. Injected cells (outlined) lacked 
detectable giantin in the absence, but not the pres-
ence, of the proteasome inhibitor. Antigiantin-
injected cells were incubated for 16 h and stained 
with anti-GPP130 (C) or anti-p115 (D). Despite 
giantin absence, injected cells exhibited normal 
staining patterns. Isolated single cells were 
injected, incubated for 20 h to allow cell division, 
and then stained for giantin (E), GPP130 (F), or 
costained for tubulin (G) and GPP130 (H). Note 
that daughter cells exhibited normal Golgi 
morphology in the absence of detectable giantin. 
Each injected cell divided in this experiment 
(n   20). Images in A, B, E, and F were acquired 
with a 20  objective. Bar, 10  m. 
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itation assay indicated that anti-GM130 antibodies, but not
control antibodies, disrupted p115–GM130 complexes pres-
ent on the membranes (Fig. 8 B). In contrast, under the
same conditions, recovery of membrane-associated p115 was
not affected by either anti-GM130 antibodies or control an-
tibodies (Fig. 8 C). Thus, disruption of p115–GM130 com-
plex formation by anti-GM130 treatment of isolated mem-
branes is not sufficient to cause membrane release of p115.
Together, these experiments indicate that microinjection of
antibodies that disrupt GM130–p115 complex formation in
vitro, cause neither p115 membrane displacement in vitro or
in vivo nor Golgi breakdown in vivo. This suggests that sim-
ilar to the situation for giantin, the essential function of
p115 in Golgi maintenance is independent of GM130.
 
Discussion
 
The model where COPI vesicles are tethered by a long gian-
tin–p115–GM130–GRASP65 complex has important im-
plications for both vesicle trafficking during interphase and
Golgi breakdown at mitosis (Sönnichsen et al., 1998). Dur-
ing intra-Golgi trafficking, tethered vesicle transport may
keep COPI vesicles physically linked to cisternae thereby
preventing diffusion away from their donor and acceptor
membranes. At the onset of mitosis, phosphorylation of sub-
units in the tether complex, such as GM130 (Nakamura et
al., 1997), would prevent complex formation leading to
release of COPI vesicles and their subsequent dispersal
throughout the cytoplasm. If one of the normal functions of
COPI vesicles is to retrieve Golgi-localized residents as cis-
ternae mature, then at mitosis, COPI vesicle formation in
the absence of docking and fusion would lead to accumula-
tion of Golgi residents in COPI vesicles. Here, we used mi-
croinjection of antibodies directed against the binding sites
in p115, giantin, and GM130, proteins implicated in tether
formation, to study the role of these interactions in vivo.
Surprisingly, anti-p115 and antigiantin antibodies caused an
apparently specific degradation of their antigens. Consistent
Figure 7. Golgi maintenance and reassembly in anti-GM130–
injected cells. Cells injected with rabbit anti-GM130 were incu-
bated for 16 h and stained using mouse antigiantin (A), or mouse 
anti-p115 (B). Isolated single cells were also injected, incubated for 
20 h to allow cell division, and then stained for GPP130 (C). Note 
that injected cells (outlined) exhibited normal patterns. Bar, 10  m.
Figure 8. Anti-GM130 blocks p115–GM130 complex formation 
without displacing membrane-associated p115. (A) NRK cell 
lysates were added to bead-attached GST-GM130 that was preincu-
bated with the amount of anti-GM130 (lanes 1–3) or anti-GST (lane 
4) indicated. The amount of cellular p115 recovered on the beads 
was determined by immunoblotting. (B) NRK membrane fractions 
were pretreated in absence (lane 1) or the presence of the indicated 
amounts of anti-GM130 (lanes 2–4) or antigiantin (lane 5) before 
coimmunoprecipitation with anti-p115 covalently attached to 
beads. The amount of cellular GM130 and p115 recovered was 
determined by immunoblotting. (C) NRK membrane fractions were 
also pretreated without antibody (lane 1), with 5  l anti-GM130 
antibody (lane 2), or with 5  l antigiantin (lane 3) and then 
collected by centrifugation. The recovery of membrane-associated 
p115 and GM130 was then determined by immunoblotting. Note 
that although anti-GM130 blocked p115 binding to GST-GM130, 
and it blocked recovery of p115–GM130 complexes from mem-
branes; it did not block p115 membrane association. Bar, 10  m. 
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with a key prediction of the model outlined above, loss of
cellular p115 induced COPI-dependent Golgi vesiculation
in interphase cells. However, cells lacking detectable giantin,
or cells containing anti-GM130 antibodies that prevented
GM130–p115 interactions, retained apparently normal Golgi
structure and disassembly/reassembly properties. These ob-
servations strongly suggest that the putative giantin–p115–
GM130–GRASP65 tether complex is not required for Golgi
structural maintenance, nor is disruption of this complex
sufficient to explain mitotic Golgi breakdown.
Although there was not an essential role for the tether
complex, our observations confirmed that p115 is required
for Golgi structural maintenance (Alvarez et al., 1999). This
indicates that p115 acts in a pathway that is independent, or
at least can function independently, of interactions with gi-
antin and GM130. Absence of p115 induced apparent accu-
mulation of Golgi vesicles suggesting that Golgi vesicle
docking is in fact a key role of p115 (Waters et al., 1992).
Anti-p115–induced Golgi vesiculation was prevented by
CBM-mediated COPI displacement, pointing to a COPI
origin for the accumulated vesicles. This is compatible with
the in vitro requirement of p115 for binding of COPI-
coated vesicles to isolated Golgi membranes (Sönnichsen et
al., 1998).
Presumably, cessation of ER to Golgi transport in anti-
p115–injected cells also contributed to loss of Golgi struc-
ture, as Golgi structure depends on input of membrane and
other factors from the ER (Storrie et al., 1998), and p115 is
required for ER to Golgi transport in semi-intact cells (Alva-
rez et al., 1999; Allan et al., 2000). There is also evidence
that p115 is required for ER to Golgi transport in intact
cells, as p115 is required for Golgi reassembly after BFA
washout (Fig. 5 B; Alvarez et al., 1999), a reaction that in-
volves transport of this type. Importantly, in semi-intact
cells, inhibition of p115 blocks transport at the step where
vesicular tubular clusters of the ERGIC would otherwise
translocate from peripheral sites in toward the juxtanuclear
Golgi complex (Alvarez et al., 1999). A role for p115 at this
step would explain why peripheral ERGIC was maintained
in the absence of p115 (Fig. 5 A) despite vesiculation of the
Golgi complex. In fact, one possibility is that p115’s sole re-
quired function is in the docking of Golgi-derived COPI-
coated retrieval vesicles with the ERGIC. This reaction may
contribute components that are essential to the translocation
and maturation of pre-Golgi elements as they form new cis-
cisternae. Components required for translocation and matu-
ration might include receptors for cytoplasmic dynein and
early Golgi enzymes, respectively. This view explains both
COPI vesicle accumulation and arrest of vesicular tubular
cluster translocation/maturation in the absence of p115. It is
also consistent with recruitment of p115 into a SNARE
complex during COPII formation (Allan et al., 2000), as
this complex would then be used for the subsequent docking
and fusion of COPI retrieval vesicles with ERGIC mem-
branes. Furthermore, this reaction may be analogous to
p115-dependent cisternal growth during in vitro Golgi reas-
sembly (Shorter and Warren, 1999).
If p115’s essential function for Golgi structure mainte-
nance is to mediate COPI vesicle docking and fusion with
the ERGIC, then this reaction apparently involves p115
binding partners other than giantin and GM130. Why then
are these proteins required in p115-dependent reactions in
vitro? One possibility is that giantin and GM130 do func-
tion together with p115 in intact cells, but that they func-
tion in transport steps other than COPI vesicle/ERGIC
docking. Further, these other functions that involve p115,
giantin, and GM130 must play a facilitating role rather than
an essential role. This would fit with their description as
tethers, because tethering is expected to be the outermost in-
teraction in a series of interactions between vesicle and target
membranes, which culminate in targeted membrane fusion.
In the absence of tethering, downstream components, such
as the interaction of cognate SNARE proteins, may suffice,
albeit less efficiently. The situation could be dramatically
different for in vitro assays. Because of dilution and disrup-
tion of spatial organizing features such as the cytoskeleton
and membrane stacking, a requirement for tethering may be
revealed. Thus, giantin and/or GM130 may function to-
gether with p115 in steps such as docking at the early Golgi
complex (Alvarez et al., 1999; Allan et al., 2000), intra-
Golgi COPI vesicle transport (Waters et al., 1992), and
Golgi stack formation (Shorter and Warren, 1999); however
not in a capacity required for Golgi biogenesis in vivo. It is
also formally possible that GM130 and giantin are mutually
redundant or that their respective functions are redundant
with as yet unidentified proteins. However, the fact that co-
injection of both antigiantin and anti-GM130 antibodies
had no detectable effect on Golgi structure argues against
mutual redundancy; and the lack of any identified proteins
with meaningful sequence similarity in the human genome
database argues against unidentified family members.
The idea that p115 plays both an essential role indepen-
dent of giantin and GM130 as well as a nonessential role in-
volving giantin and GM130 helps explain the noted lack of
Golgi structural perturbation in cells where the GM130
NH
 
2
 
 terminus was used to displace p115 from the Golgi ap-
paratus (Seemann et al., 2000). Displacement of p115 from
the Golgi complex, may block the nonessential role but have
no effect on the essential role, as the essential role may in-
volve, not Golgi-localized p115, but rather ERGIC-localized
p115 initially recruited to membranes during COPII vesicle
formation (Allan et al., 2000). This model could also ac-
count for the apparent sequential action of p115 relative to
giantin and GM130 in semi-intact cell transport from the
ER to the medial-Golgi complex (Alvarez et al., 2000), as
the putative role of p115 in ERGIC/COPI docking is up-
stream of its putative role in docking at, or within, the Golgi
complex. Also, the model is consistent with the fact that the
 
Saccharomyces cerevisiae
 
 homologue of p115, Uso1p, is es-
sential for viability (Nakajima et al., 1991), whereas this
yeast does not have homologues for either giantin or
GM130. Furthermore, the Uso1p acidic domain, which
would be expected to mediate interaction with giantin or
GM130 homologues, if they existed, is not required for
growth (Seog et al., 1994).
Does tether inhibition at mitosis lead to Golgi vesicula-
tion? Golgi breakdown in interphase cells in response to
anti-p115–induced p115 degradation mimicked, to a first
approximation, Golgi vesiculation in mitotic cells. This sug-
gests that inhibition of p115 may play a major role in mi- 
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totic Golgi vesiculation. Indeed, there is evidence suggesting
that at least the nonessential role of p115 is inhibited at mi-
tosis, as p115’s ability to interact with giantin and GM130 is
reduced by dephosphorylation (Dirac-Svejstrup et al., 2000)
and p115 becomes dephosphorylated at M-phase (Sohda et
al., 1998). On the other hand, p115 inhibition is not likely
to be the sole requirement for mitotic breakdown because
the time course of the interphase breakdown (
 
t
 
1/2
 
 
 
  
 
2 h) was
considerably slower than that which occurs from prophase
to metaphase (
 
 
 
30 min), even after accounting for the rate
of p115 degradation (
 
t
 
1/2
 
 
 
  
 
1 h). With regard to giantin and
GM130, absence of detectable giantin (Fig. 6) and preven-
tion of GM130–p115 interactions (Fig. 7) did not cause
Golgi breakdown. This argues that mitotic phosphorylation
of GM130 (Lowe et al., 1998), which prevents p115 bind-
ing (Nakamura et al., 1997), and mitotic phosphorylation of
giantin (unpublished results) are not sufficient to cause
Golgi vesiculation, although inhibition of these proteins by
phosphorylation may still contribute to the vesiculation re-
action. Further, these results suggest that one of the reac-
tions that may be involved, in addition to p115 inhibition at
mitosis, would be the inhibition of those transport factors
that act immediately after the tethers in the docking and fu-
sion of Golgi-derived vesicles.
Also noteworthy, was the phenomena of antibody-induced
antigen degradation. To our knowledge this has not been
previously observed, perhaps because many other studies
have not stained for the corresponding antigen in anti-
body-injected cells. Because the loss of staining was time,
temperature, and proteasome dependent, and because it
followed an apparent clustering of the antigen, we suspect
that antibody-induced cross-linking of the antigen some-
how triggered binding and ubiquitination of the antigens
by a ubiquitin ligase. In the case of giantin and the Golgi-
localized fraction of p115, this was probably followed by
proteasome recruitment to the Golgi membrane. The roles
of cross-linking, ubiquitination, and proteasome localiza-
tion are important subjects for future study. Giantin and
p115 are long-lived proteins suggesting that targeted deg-
radation does not normally play an important role in their
regulation. Rather, the antibody-induced degradation of
these antigens suggests that if the mechanism can be un-
derstood, it may be possible to engineer antibodies that
cause degradation of any antigen of interest. This could be
significant for further tests of in vivo function by creation
of “knock-outs” without requiring targeted gene disrup-
tion or antisense RNA. In the cases of anti-p115–induced
p115 degradation and antigiantin-induced giantin degra-
dation examined here, this phenomena provided strong
support for the hypothesis that the essential function of
p115 in Golgi structure is independent of its hypothe-
sized role in a giantin–p115–GM130–GRASP65 tether
and sets the stage for further work into the roles of these
proteins.
 
Materials and methods
 
Reagents and antibodies
 
Cyclohexanebis(methylamine) (CBM) (Sigma-Aldrich) was added directly
to culture medium. High purity digitonin (Boehringer), brefeldin A (Sigma-
 
Aldrich), and MG-132 (Calbiochem) were stored in DMSO at –20
 
 
 
C as 20,
10, and 10 mg/ml stocks, respectively. Antiglutathione 
 
S
 
-transferase (GST),
anti-p115, antigiantin, and anti-GM130 antibodies for microinjection were
prepared as follows. GST-p115 (710–959), GST-giantin (1–469), and GST-
GM130 (1–74) were generated (Linstedt et al., 2000) and used to immu-
nize rabbits (Covance). High-titer bleeds were partially purified by ammo-
nium sulfate precipitation. In the case of the anti-p115 sera, antibodies
with anti-GST reactivity were first removed by affinity purification on GST-
coupled beads that were prepared by allowing 2 ml of purified GST (5 mg/
ml) to react with 0.5 ml Affi-gel beads (Bio-Rad Laboratories). These were
used for control microinjections. The remaining antibodies with anti-p115
reactivity were then similarly purified on p115-coupled beads that were
prepared by allowing 0.5 ml purified GST-p115 (2 mg/ml) to react with 0.2
ml Affi-gel beads. The resulting affinity purified antibodies were ammo-
nium sulfate precipitated, dialyzed against KH buffer (125 mM potassium
acetate, 25 mM Hepes), adjusted to 2 mg/ml, aliquoted, and snap-frozen.
Antigiantin and anti-GM130 antibodies were dialyzed against KH buffer,
aliquoted, and snap-frozen at 14 mg/ml. Antibodies used for immunofluo-
rescence staining were against: GPP130 (A1–118; Linstedt et al., 1997), gi-
antin (G1–133; Linstedt and Hauri, 1993; and FITC-labeled antigiantin
pAb), 
 
 
 
-COP (mAD; Sigma-Aldrich), p115 (7D1; provided by M.G. Wa-
ters, Princeton University, Princeton, NJ), GM130 (provided by G. Warren,
Yale, New Haven, CT), ERGIC-53 (G1–93; provided by H.-P. Hauri,
Biozentrum of the University of Basel, Basel, Switzerland), tubulin (ICN
Biomedicals), and KDEL receptor (StressGen Biotechnologies).
 
Microinjection and analysis
 
HeLa cells were cultured on glass coverslips as described (Lee and Linst-
edt, 1999). For CBM treatments, the coverslips were coated with SuperFi-
bronectin (Sigma-Aldrich). Before microinjection, the culture medium was
adjusted to 25 mM Hepes-KOH (pH 7.4) and the thawed antibody aliquots
were centrifuged at 100,000 rpm for 1 h in a TLA 100.3 rotor (Beckman
Coulter). The cells were maintained at 37
 
 
 
C, injected using an Eppendorf
microinjection system, and then were returned to the incubator. Staining
and digital image acquisition were as previously described (Linstedt et al.,
1997). Using the injected antibody staining pattern and the Trace Contour
command in Adobe Photoshop, the injected cells were outlined. In certain
cases, the staining of the injected antibody was omitted to exclude any
possibility of bleedthrough. For digitonin release, each coverslip was incu-
bated for 6 min at room temperature in 0.5 ml of 0.04 mg/ml digitonin in
KHM (100 mM KCl, 25 mM Hepes-KOH 7.4, 2.5 mM magnesium acetate)
before fixation. Mean cytoplasmic fluorescence was measured from
10,125 pixels in each cell, manually excluding the juxtanuclear area, us-
ing the Histogram function in Adobe Photoshop. Background, taken as the
average pixel value outside the cells, was subtracted.
 
Binding experiments
 
For measuring binding of p115 to GST-GM130, normal rat kidney (NRK)
cells were lysed in HKT (10 mM Hepes-KOH, pH 7.2, 100 mM KCl, 1 mM
EDTA, 0.5% Triton X-100) and the lysate cleared by centrifugation at
100,000 rpm in the TLA 100.3 rotor. The cleared lysate (0.1 ml) was then
added to a mixture of 5 
 
 
 
l GST-GM130–coated glutathione-agarose beads
(
 
 
 
0.04 mg/ml) and the indicated amounts of the anti-GM130 or anti-GST
polyclonal antibodies. After rotation for 60 min at 4
 
 
 
C, the beads were
washed four times with 1 ml of HKT and eluted with 0.5 ml of 0.6 M KCl in
HKT. Immunoblotting of the eluate was as described (Linstedt et al., 2000).
To test for co-immunoprecipitation of p115–GM130 complexes from anti-
body-treated membranes, NRK cells were homogenized in KHM using a
25-gauge needle and centrifuged to obtain a postnuclear supernatant. The
postnuclear supernatant was then underlayed with 10 
 
 
 
l of 80% sucrose
and centrifuged at 16,000 
 
g
 
 for 20 min at 4
 
 
 
C. The membranes were col-
lected and incubated with various amounts of anti-GM130 or antigiantin
polyclonal antibodies for 60 min on ice. The membranes were then solubi-
lized with HKT and the lysate was centrifuged at 50,000 rpm in the TLA
100.3 rotor for 30 min. The cleared lysate was rotated at 4
 
 
 
C for 60 min
with 20 
 
 
 
l of packed Affi-Gel beads that had been coupled to the anti-p115
polyclonal antibody (Bio-Rad Laboratories). Washing, elution, and detec-
tion were then performed as before. To assay membrane-associated p115
after anti-GM130 or antigiantin incubation, membranes were prepared and
incubated with antibodies exactly as just described. The antibody-treated
membranes were then adjusted to 1 ml KHM, underlayed with 10 
 
 
 
l of
80% sucrose, and centrifuged as before. After four such washes the amount
of p115 and GM130 was determined by immunoblotting.
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